TARPON SPRINGS, Fla., July 7, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib ...
LINCOLN, Neb--(BUSINESS WIRE)--Celerion, a leading clinical research organization, proudly announces its recent achievement of obtaining the Clinical Laboratory Improvement Amendments (CLIA) ...
On July 16, 2026, the Centers for Medicare & Medicaid Services (CMS) and the Centers for Disease Control and Prevention (CDC) ...
QuidelOrtho Corporation QDEL recently announced that it has been granted a CLIA Waiver by the FDA, which applies to its new Sofia 2 SARS Antigen+ FIA (fluorescent immunoassay). The Sofia 2 SARS ...
Firm will configure MutliGen tests on transrenal platform. Molecular diagnostics firm TrovaGene is to acquire MultiGen Diagnostics’ CLIA-certified laboratory in return for 750,000 shares of TrovaGene ...
Chandigarh: To strengthen blood safety in Punjab, the state is adopting advanced testing technologies, including Nucleic Acid Testing (NAT) and Chemiluminescence Immunoassay (CLIA), which enhance the ...
The FDA requires that biomarker testing to select patients for registration trials must be performed in a CLIA-certified laboratory environment CLIA certification for the Allarity Therapeutics Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results